Effects of pirenzepine ophthalmic solution on form-deprivation myopia in the guinea pigs

Chinese Medical Journal

Volumn 118, Issue 7, 2005, Pages 561-566

  Le, Qi Hua ^a   Cheng, Neng Neng ^a   Wu, Wei ^a   Chu, Ren Yuan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Myopia; Ophthalmic solutions; Pharmacology; Pirenzepine

Indexed keywords

ATROPINE; EYE DROPS; MUSCARINIC M1 RECEPTOR ANTAGONIST; PIRENZEPINE; SODIUM CHLORIDE; MUSCARINIC RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMETRY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; ENUCLEATION; EYE REFRACTION; EYELID; GUINEA PIG; HISTOPATHOLOGY; IN VIVO STUDY; MONOCULAR DEPRIVATION; MYOPIA; NONHUMAN; ORGAN WEIGHT; STATISTICAL ANALYSIS; SUTURE; VITREOUS BODY; ANIMAL; DRUG EFFECT; EYE; ORGAN SIZE; PATHOLOGY;

ANIMALS; EYE; GUINEA PIGS; MUSCARINIC ANTAGONISTS; MYOPIA; OPHTHALMIC SOLUTIONS; ORGAN SIZE; PIRENZEPINE; REFRACTION, OCULAR;

EID: 17144419256     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Sperduto RD, Seigel D, Roberts J, et al. Prevalence of myopia in the United States. Arch Ophthalmol 1983; 101:405-407.
2. Qiao-Grider Y, Hung LF, Kee CS, et al. Recovery from form-deprivation myopia in rhesus monkeys. Invest Ophthalmol Vis Sci 2004;45:3361-3372.
3. McKanna JA, Casagrande VA. Atropine affects lid suture myopia development. Doc Ophthalmol Proc Series 1981;28:187-192.
4. Cottriall CL, McBrien NA. The M1 muscarinic antagonist pirenzepine reduces myopia and eye enlargement in the tree shrew. Invest Ophthalmol Vis Sci 1996;37:1368-1379.
5. Cottriall CL, McBrien NA, Annies R, et al. Prevention of form-deprivation myopia with pirenzepine: a study of drug delivery and distribution. Ophthalmic Physiol Opt 1999;19:327-335.
6. Shi JB, Xu JT, Xia CY, et al. Quantitative study of normal retinal structure in guinea pig. Chin Ophthal Res (Chin) 1999;17:98-100.
7. Wiesel TN, Raviola E. Myopia and eye enlargement after neonatal lid fusion in monkey. Nature 1977;226: 66-68.
8. Xi XQ, Chu RY, Zhou XT, et al. Retinal dopamine transporter in experimental myopia. Chin Med J 2002; 115:1027-1030.
9. Xi XQ, Chu RY, Chen RJ. Observation on histopathology and ultrastructure of experimental myopia. Rec Adv Ophthalmol (Chin) 2001;21:329-331.
10. Gentle A, Truong HT, McBrien NA. Glyco-saminoglycan synthesis in the separate layers of the chick sclera during myopic eye growth: comparison with mammals. Curr Eye Res 2001;23:179-184.
11. Norton TT, Rada JA. Reduced extracellular matrix in mammalian sclera with induced myopia. Vision Res 1995;35:1271-1281.
12. Truong HT, Cottriall CL, Gentle A, et al. Pirenzepine affects scleral metabolic changes in myopia through a non-toxic mechanism. Exp Eye Res 2002;74:103-111.
13. Leech EM, Cottrial CL, McBrien NA. Pirenzepine prevents form deprivation myopia in a dose-dependent manner. Ophthal Physiol Opt 1995;15:351-356.
14. Wilkinson GR. Pharmacokinetics: The dynamics of drug absorption, distribution and elimination. In: Hardman JG, LimBird LE, eds. Goodman & Gilman's the pharmacological basis of therapeutics, tenth ed. New York: McGraw-Hill Medical Publishing Division; 2001:3-18.
15. Moroi SE, Lichter PR. Ocular pharmacology. In: Hardman JG, LimBird LE, eds. Goodman & Gilman's the pharmacological basis of therapeutics, tenth ed. New York: McGraw-Hill Medical Publishing Division; 2001:1827-1829.
16. Dai YK, Chu RY. The pharmacokinetics of pirenzepine in the aqueous humor of rabbits. Chin J Optom Ophthalmol (Chin) 2002;4:228-229.
17. Xi NZ. Ophthalmic solution, nasal solution and others. In: Xi NZ ed. Parmaceutics, third ed. Beijing: People's Medical Publishing House; 1995:221-225.
18. Ouyang CH, Chu RY, Hu WZ. Effects of pirenzepine on lens-induced myopia in the guinea-pig. Chin J Ophthalmol (Chin) 2003;39:348-351.
19. Pang IH, Matsumoto S, Tamm E, et al. Characterization of muscarinic receptor involvement in human ciliary muscle cell function. J Ocular Pharmacol 1994;10:125-136.
20. Jumblatt JE, Hackmiller RC. M2-type muscarinic receptors mediate prejunctional inhibition of norepinephrine release in human iris-ciliary body. Exp Eye Res 1994;58:175-180.
21. Bartleft JD, Niemann K, Houde B, et al. A tolerability study of pirenzepine ophthalmic gel in myopic children. J Ocul Pharmacol Ther 2003;19:271-279.